Skip to Main Content

After the World Health Organization recommended a Roche (RHHBY) drug to treat severe Covid-19, Doctors Without Borders quickly urged the drug maker to “end its monopoly” by lowering the price of the medicine and sharing its technology in order to quickly widen access.

Meta-analyses of more than 10,000 patients who were enrolled in 27 clinical trials founds that two medicines — Roche’s Actemra and Kevzara from Sanofi — lowered the risk of death by 13% compared to standard care, especially when given with corticosteroids. The WHO noted these were the first drugs to be found effective against Covid-19 since corticosteroids were recommended last September.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment